Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Sylvia C. FormentiBenjamin Izar, Timothy E. McGraw
Dive into the research topics of 'Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial'. Together they form a unique fingerprint.